Vigabatrin
- Generic Name
- Vigabatrin
- Brand Names
- Sabril, Vigadrone, Kigabeq
- Drug Type
- Small Molecule
- Chemical Formula
- C6H11NO2
- CAS Number
- 68506-86-5
- Unique Ingredient Identifier
- GR120KRT6K
- Background
Vigabatrin is an analog of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although administered as a racemic mixture, only t...
- Indication
Vigabatrin is indicated as adjunctive therapy in the treatment of refractory complex partial seizures in patients 2 years of age and older who have had inadequate responses to multiple previous treatments (i.e. not to be used for first-line therapy). It is also indicated as monotherapy in the treatment of infantile spasms in patients between 1 month and 2 ye...
- Associated Conditions
- Infantile Spasms (IS), Refractory Complex partial seizures
- Associated Therapies
- -
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Katarzyna Kotulska
- Target Recruit Count
- 60
- Registration Number
- NCT04987463
- Locations
- 🇵🇱
Children's Memorial Health Institute, Neurology and Epileptology, Warsaw, Poland
🇵🇱Medical University of Warsaw, Department of Pediatric Neurology, Warsaw, Poland
Vigabatrin and Insulin Sensitivity
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 4
- Registration Number
- NCT04321395
- Locations
- 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03421496
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Beaumont Children's Hospital, Royal Oak, Michigan, United States
🇺🇸Akron Children's Hospital, Akron, Ohio, United States
A Novel Approach to Infantile Spasms
- Conditions
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 394
- Registration Number
- NCT03347526
- Locations
- 🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇺🇸Atrium Health, Charlotte, North Carolina, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Population Pharmacokinetics of Antiepileptic in Pediatrics
- Conditions
- Interventions
- Biological: Valproic acidBiological: carbamazepineBiological: phenobarbitalBiological: phenytoinBiological: levetiracetamBiological: lamotrigineBiological: topiramateBiological: oxcarbazepineBiological: stiripentolBiological: clobazamBiological: brivaracétamBiological: felbamateBiological: lacosamideBiological: rufinamideBiological: gabapentineBiological: pregabalineBiological: sultiameBiological: tiagabineBiological: vigabatrineBiological: mesuximideBiological: primidoneBiological: perampanelBiological: ethosuximideBiological: zonisamideBiological: cannabidiolOther: genetic polymorphisms
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1000
- Registration Number
- NCT03196466
- Locations
- 🇫🇷
AP-HP Cochin, Paris, France
Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- The Hospital for Sick Children
- Registration Number
- NCT02299115
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Barbara J. Coffey
- Target Recruit Count
- 4
- Registration Number
- NCT01585207
- Locations
- 🇺🇸
Tics and Tourette's Clinical and Research Program, New York, New York, United States
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Lundbeck LLC
- Registration Number
- NCT01413711
Vigabatrin for Cocaine and Alcohol Dependence
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 32
- Registration Number
- NCT01335867
- Locations
- 🇺🇸
University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania, United States
Vigabatrin for the Treatment of Cocaine Dependency
- Conditions
- Interventions
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Catalyst Pharmaceuticals, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT01281202
- Locations
- 🇺🇸
Mountain Manor Treatment Center @ Baltimore, Baltimore, Maryland, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Matrix Institute on Addictions, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.